IcoSema, a combination therapy of basal insulin icodec and semaglutide, achieves a noninferior reduction in A1c levels compared with basal-bolus therapy in adults with T2D.

In a small cell therapy trial, 10 out of 12 people with type 1 diabetes no longer needed supplemental insulin, even a year after treatment.

Stem cell therapy has restored insulin production in about 10 patients with Type 1 diabetes, according to a study published ...

Pregnant women with type 1 diabetes who used hybrid closed-loop insulin delivery with Control-IQ technology spent more time ...

The addition of anagliptin to insulin and metformin therapy may improve glycemic control in patients with type 2 diabetes while maintaining an acceptable safety profile.

After a one-year follow-up, 10 of 12 patients given the islet cell therapy zimislecel no longer required insulin. Vertex ...

A new study found that Ozempic's main ingredient may treat people with type 1 diabetes, control blood sugar, and lose weight.

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

Researchers have bioprinted human islets designed to mimic the body’s own tissue structure, allowing them to integrate ...

Once-weekly efsitora vs once-daily degludec was associated with comparable glycemic control outcomes and improved ...

"Regulatory T cells (Treg cells) play a crucial role in maintaining immune homeostasis. As such, Immuthera’s and PolTREG’s delivery of Tregs offers hope for curing or controlling autoimmune diseases, ...

Zimislecel, a novel stem cell therapy, has reportedly demonstrated promising results in an early-phase clinical trial ...